Can we predict which patients with implantable cardioverter defibrillators receive appropriate shock therapy? A study of 155 patients

被引:9
|
作者
Rinaldi, CA [1 ]
Simon, RDB [1 ]
Baszko, A [1 ]
Bostock, J [1 ]
Elliot, D [1 ]
Bucknall, C [1 ]
Gill, JS [1 ]
机构
[1] Guys & St Thomas Hosp, Ctr Cardiothorac, London SE1 7EH, England
关键词
implantable cardioverter defibrillators; shock therapy;
D O I
10.1016/S0167-5273(02)00364-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Appropriate shock therapy (AST) occurs in the minority of patients with implantable cardioverter defibrillators (ICDs). We assessed which patients received AST and whether there were any predictive factors. Methods: We retrospectively analysed data from 155 patients implanted with ICDs at our institution from a period from February 1984 to February 2001. Stored electrogram data were analysed. We sub-divided patients on the basis of underlying cardiac disease. Various clinical echocardiographic and electrophysiological variables were studied. Results: AST occurred in 53 (34%) of patients (Group 1) and no AST in 102 (64%) of patients (Group 2). Impaired LV function was significantly associated with AST. Group I patients had a lower ejection fraction (EF) compared to Group 2 (37.5+/-13% vs. 47.8+/-14%, P<0.0001). Seventy-two percent of patients with AST had an EF <40% vs. 35% of patients in Group 2 (P<0.0001). NYHA Class was also associated with AST, 42% of Group 1 were in NYHA Class III/IV vs. 12% in Group 2 (P<0.001). Programmed electrical stimulation (PES) was a predictor of AST. PES was positive in a greater proportion of patients in Group I vs. 2 (88% vs. 64%, P<0.0006). Sub-group analysis showed that patients with dilated cardiomyopathy (DCM) had a high incidence of AST (80%). In these patients PES was a poor predictor of AST being positive in only 25%. Conclusion: AST occurs in the minority of our patients. Certain pre-procedural variables predict AST. PES does not appear useful in predicting shock therapy in DCM patients and a negative PES should not preclude ICD implantation in this group. (C) 2002 Published by Elsevier Science Ireland Ltd.
引用
收藏
页码:69 / 75
页数:7
相关论文
共 50 条
  • [31] Eligibility of cardiac resynchronization therapy patients for subcutaneous implantable cardioverter defibrillators
    Giammaria, Massimo
    Lucciola, Maria Teresa
    Amellone, Claudia
    Orlando, Fabrizio
    Mazzone, Giuseppe
    Chiarenza, Sara
    Lovecchio, Mariolina
    Valsecchi, Sergio
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2019, 54 (01) : 49 - 54
  • [32] Predictors of appropriate therapy from implantable cardioverter-defibrillators in Scandinavian arrhythmogenic right ventricular cardiomyopathy patients
    Platonov, P. G.
    Haugaa, K. H.
    Jensen, H. K.
    Bundgaard, H. K.
    Svensson, A.
    Gilljam, T.
    Hansen, J.
    Eschen, O.
    Edvardsen, T.
    Svendsen, J. H.
    EUROPEAN HEART JOURNAL, 2015, 36 : 42 - 42
  • [33] Eligibility of cardiac resynchronization therapy patients for subcutaneous implantable cardioverter defibrillators
    Moubarak, Ghassan
    Maison-Blanche, Pierre
    Thomas, Olivier
    JOURNAL OF ELECTROCARDIOLOGY, 2018, 51 (03) : 531 - 533
  • [34] Renal dysfunction and appropriate shock therapy in Implantable Cardioverter Defibrillator patients with nonischemic heart failure
    Takahashi, Atsushi
    Shiga, Tsuyoshi
    Futagawa, Keisuke
    Kimura, Ryusuke
    Elima, Koichiro
    Manaka, Tetsuyuki
    Tanizaki, Kouhei
    Shoda, Morio
    Hagiwara, Nobuhisa
    Kasanuki, Hiroshi
    CIRCULATION, 2007, 116 (16) : 441 - 441
  • [35] Appropriate Shocks and Mortality in Patients With Versus Without Diabetes With Prophylactic Implantable Cardioverter Defibrillators
    Junttila, M. Juhani
    Pelli, Ari
    Kenttae, Tuomas V.
    Friede, Tim
    Willems, Rik
    Bergau, Leonard
    Malik, Marek
    Vandenberk, Bert
    Vos, Marc A.
    Schmidt, Georg
    Merkely, Bela
    Lubinski, Andrzej
    Svetlosak, Martin
    Braunschweig, Frieder
    Harden, Markus
    Zabel, Markus
    Huikuri, Heikki V.
    Sticherling, Christian
    DIABETES CARE, 2020, 43 (01) : 196 - 200
  • [36] INCIDENCE OF MORTALITY AND APPROPRIATE SHOCKS IN DIABETIC PATIENTS AFTER RECEIVING IMPLANTABLE CARDIOVERTER -DEFIBRILLATORS
    Desai, H.
    Lai, H.
    Aronow, W.
    Amin, H.
    Gandhi, K.
    Frishman, W.
    Ravipati, G.
    Weiss, M.
    Cohen, M.
    Sorbera, C.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2009, 57 (04) : 618 - 618
  • [37] Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators
    Ho, AT
    Pai, SM
    Timothy, P
    Pal, RG
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2005, 28 (07): : 647 - 653
  • [38] Adjunctive therapy for recurrent ventricular tachycardia in patients with implantable cardioverter defibrillators
    Reiffel J.A.
    Current Cardiology Reports, 2007, 9 (5) : 381 - 386
  • [39] Eligibility of cardiac resynchronization therapy patients for subcutaneous implantable cardioverter defibrillators
    Massimo Giammaria
    Maria Teresa Lucciola
    Claudia Amellone
    Fabrizio Orlando
    Giuseppe Mazzone
    Sara Chiarenza
    Mariolina Lovecchio
    Sergio Valsecchi
    Journal of Interventional Cardiac Electrophysiology, 2019, 54 : 49 - 54
  • [40] Are we overestimating percentage of right ventricular pacing in patients with implantable cardioverter defibrillators?
    Olshansky, Brian
    Sandesara, Chirag
    Moore, Stephen
    Day, John D.
    Kalahasty, Gautham
    Cullinane, David
    Johnson, Tim
    Treat, Stephen
    Brown, Scott
    Lerew, Darin R.
    JOURNAL OF CARDIAC FAILURE, 2006, 12 (06) : S68 - S68